Thibaut De Smedt

Thibaut is a Venture Partner at Medicxi. Prior to joining Medicxi, Thibaut co-founded three early-stage biotechnology companies (AiDD, Immuthes and xSeedD). He was previously Research Director at Addex Therapeutics (focused on allosteric drug development), Senior Group Leader at Apoxis (a spinout from the University of Lausanne) and Research Scientist at Amgen (developing therapies for cancer and inflammation).  

Thibaut has co-founded multiple Medicxi companies, including KliRNA and Depth Charge and supports various portfolio companies, including Petalion Therapeutics, Cosmyc Therapeutics and Ethyreal.

Thibaut received a PhD in Molecular Biology and Immunology from the Université Libre de Bruxelles, Belgium and conducted postdoctoral research at Immunex in Seattle, USA. He is currently managing director at Immuthes and xSeedD.